OncoMatch/Clinical Trials/NCT06321484
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Is NCT06321484 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cytokine-Induced Memory-like Natural Killer Cells and Interleukin 2 for platinum-resistant ovarian cancer.
Treatment: Cytokine-Induced Memory-like Natural Killer Cells · Interleukin 2 — The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: BRCA1 germline or somatic mutation
Patients with germline or somatic BRCA1 or BRCA2 mutations must have received prior PARP inhibitor therapy as maintenance or treatment.
Allowed: BRCA2 germline or somatic mutation
Patients with germline or somatic BRCA1 or BRCA2 mutations must have received prior PARP inhibitor therapy as maintenance or treatment.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Patients must have received at least 1 lines of prior systemic therapy and be deemed platinum resistant/intolerant by their treating oncologist.
Must have received: PARP inhibitor — maintenance or treatment
Patients with germline or somatic BRCA1 or BRCA2 mutations must have received prior PARP inhibitor therapy as maintenance or treatment.
Cannot have received: anti-tumor chemotherapy or other investigational agents
Participants who have had anti-tumor chemotherapy or other investigational agents within two weeks prior to NK cell infusion (6 weeks for nitrosoureas or mitomycin C)
Cannot have received: immunotherapy
immunotherapy within 6 weeks prior
Cannot have received: systemic corticosteroid therapy (prednisone)
Systemic corticosteroid therapy (> 10 mg of prednisone or equivalent dose of systemic steroids for at least 4 weeks prior to NK cell infusion)
Lab requirements
Blood counts
Absolute neutrophil count ≥1,000/mcL; Platelets ≥75,000/mcL
Kidney function
Serum creatinine ≤ 2.0 mg/dL OR glomerular filtration rate (GFR) ≥40 mL/min/1.73 m2
Liver function
AST(SGOT)/ALT(SGPT) ≤3 x institutional ULN; Total bilirubin ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then < 3 x ULN)
Cardiac function
Oxygen saturation: ≥ 90% on room air; Left ventricular ejection fraction (cardiac function) ≥ 40%; No laboratory evidence of ongoing hemolysis in opinion of investigator
Participants must meet the following organ and marrow function as defined below: Absolute neutrophil count ≥1,000/mcL; Platelets ≥75,000/mcL; AST(SGOT)/ALT(SGPT) ≤3 x institutional ULN; Total bilirubin ≤1.5 x institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then < 3 x ULN); Serum creatinine ≤ 2.0 mg/dL OR glomerular filtration rate (GFR) ≥40 mL/min/1.73 m2; Oxygen saturation: ≥ 90% on room air; Left ventricular ejection fraction (cardiac function) ≥ 40%; No laboratory evidence of ongoing hemolysis in opinion of investigator
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify